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Raised inflammatory markers
What is the evidence for using C reactive protein, erythrocyte sedimentation rate, and plasma
viscosity in diagnosis?
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This series of occasional articles provides an update on the best use
of key diagnostic tests in the initial investigation of common or important
clinical presentations. The series advisers are Steve Atkin, professor,
head of department of academic endocrinology, diabetes, and
metabolism, Hull York Medical School; and Eric Kilpatrick, honorary
professor, department of clinical biochemistry, Hull Royal Infirmary, Hull
York Medical School. To suggest a topic for this series, please email
us at practice@bmj.com.
A 72 year old man consulted a general practitioner colleague
of ours last week complaining of a non-specific feeling of
malaise for about three weeks, with mild headache and pain in
his left knee. He has generalised moderate osteoarthritis, mainly
affecting his back and both knees. Our colleague had found
nothing relevant on examination and had ordered several blood
tests. A full blood count and liver and renal function were
normal, but the erythrocyte sedimentation rate was moderately
raised at 35 mm/h.
What is the role of inflammatorymarkers?
Measurement of inflammatory markers has twomain functions:
to detect acute inflammation that might indicate specific
diseases, or to give a marker of treatment response (we will not
consider this second indication here). Measurement of
inflammatory markers can also be used as a general, but
non-specific, test for serious underlying disease. Inflammatory
markers are measured in about 4% of general practitioner
consultations, for a range of indications, with 44-47% requested
for specific diagnostic purposes, 27-33% for monitoring of
disease, and 14-28% for non-specific diagnostic purposes.1 2
There is considerable inter-practice variation in themeasurement
of inflammatory markers and in general practitioners’ responses
to abnormalities.1 3 4 We found no health-economic analyses of
these tests, but the total costs of testing must be considerable.
For example, 63 000 primary care requests for inflammatory
markers are tested annually at the University Hospitals Bristol
NHS Foundation Trust, which serves a population of about 300
000 in 40 general practices (personal communication, W
Woltersdorf, 2011).
Diseases with prominent activation of the inflammatory response
fall into three main groups: infections, autoimmune diseases,
and some haematological malignancies. Inflammatory markers
include C reactive protein (CRP), erythrocyte sedimentation
rate, plasma viscosity, fibrinogen, ferritin, and several other
acute phase proteins, though only the first three are commonly
referred to as inflammatory markers. CRP is considered to be
particularly useful in detecting bacterial infection.4 Plasma
viscosity is now generally preferred to the erythrocyte
sedimentation rate (ESR), as it is unaffected by anaemia or
polycythaemia, or by delays between sampling and
measurement, and has results independent of age or sex.5 All
these factors potentially affect the ESR. The change to use of
viscosity is relatively recent, so most reports have studied the
ESR or CRP. This article considers the evidence for and the
rational use of CRP, ESR, and viscosity in diagnosis, both for
specific diseases and non-specifically.
Diagnostic testing for specific diseases
The classic conditions for which testing may be useful are
polymyalgia rheumatica or giant cell arteritis, recently reviewed
in the BMJ.6 Systemic features may predominate, with myalgia
or headache minor or absent. A normal viscosity or ESR and
normal CRP virtually rules out the condition. False negative
results are rare—probably below 3%—though studies examining
this required a positive result from a temporal artery biopsy, so
the patients evaluated would have had more severe disease.6
Another condition with characteristic raised inflammatory
markers is myeloma.7 If polymyalgia rheumatica, giant cell
arteritis, or myeloma are suspected, measurement of
inflammatory markers is a simple “rule out” test: normal
inflammatory markers make the chance of any of these diseases
being present so low as to allow the clinician to omit specific
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Learning points
Normal levels of inflammatory markers are valuable in ruling out a few specific conditions, notably polymyalgia rheumatica, giant cell
arteritis, myeloma, and infection of hip revisions
Raised levels of inflammatory markers may be found in many other conditions, particularly infections, autoimmune conditions, and
certain cancers. In these cases, they increase the probability of the condition being present, but additional information would be needed
to be confident the disease is present or absent
Inflammatory markers are too non-specific to be a useful tool for diagnosing serious underlying disease and should rarely be used in
this situation
In an incidental finding of raised levels of inflammatory markers, if history and examination yield no clues as to cause, it is reasonable
to wait and see if symptoms develop. If levels are markedly raised (such as ESR >100 mm/h), the likelihood of disease is much higher,
but history, examination, and focused investigations are usually sufficient to establish a diagnosis
testing with protein electrophoresis and urinary Bence Jones
protein.7
CRP and ESR have been studied as an aid to differentiating
between minor illness and more serious disease, either in
primary care or emergency departments. Some subjects have
been systematically reviewed (table 1⇓). Most of these reviews
show amoderate relation between raised inflammatory markers
and the target condition, but almost always the authors
concluded that the sensitivities and specificities, on their own,
were insufficient to rule in or rule out the condition safely. This
was particularly so for primary care, where the prevalence of
the target condition is usually lower. However, inflammatory
markers may have some value as part of a clinical prediction
rule incorporating other relevant clinical features, such as fever,
although none seems to have entered mainstream clinical
practice. One reason for this may be the inevitable delay in
obtaining a result if the specimen requires analysis off site.
Recent studies have examined whether CRP testing influences
the decision to prescribe antibiotics for respiratory infections
in primary care. One study in Norway, Sweden, and Wales
found that the CRP result was the strongest influence on the
decision to prescribe antibiotics, outweighing physical signs
such as crackles on auscultation.18 A cluster randomised trial in
the Netherlands examined the effect of two interventions: CRP
testing or training in enhanced communication skills. Antibiotic
prescribing was significantly reduced in both intervention
groups—from 57% in control patients to 43% for those whose
doctors were in an intervention group.19 General practitioners
responded positively to having point of care access to CRP, as
it enhanced patients’ and general practitioners’ confidence in
prescribing decisions and empowered the doctors to prescribe
antibiotics less often.20 In all these studies, negative tests seemed
to give the doctors additional confidence in avoiding prescription
of antibiotics: this is clinically supported by the negative
likelihood ratio of 0.33,11 meaning that bacterial infection is
about a third less likely once a negative test has been reported.
The health economic aspects of point of care access to CRP
testing would need to be examined before its use was to be
recommended.
Observational studies have shown that inflammatory markers
may be raised in ovarian, renal, and colorectal cancers,
especially in advanced disease.21-23 However, has been shown
to have no discriminatory value in diagnosing these conditions,
even in secondary care, where there is a higher prevalence than
in primary care.24
In summary, there are a few clinical situations in which testing
of inflammatory markers is the optimum test, as either a “rule
in” or a “rule out” test. These include suspected polymyalgia
rheumatica or giant cell arteritis, myeloma (ESR or viscosity),
and infection of hip revisions (ESR or CRP). In most conditions,
however, there is only a moderate association between raised
inflammatory markers and the disease of interest, so they can
refine the probability of disease, particularly if the test result is
used in conjunction with other factors, such as symptoms.
Non-specific testing for systemic disease
The previous paragraphs focus on the value of inflammatory
markers when a specific disease is being considered. However,
another use is as a general marker to differentiate between the
presence and absence of disease. Several old, mostly small,
studies have examined this use (table 2⇓).25 Generally, when
general practitioners test inflammatory markers for non-specific
purposes the results are afterwards seen as being of little or no
clinical value.2 “Incidental” abnormalities in inflammatory
markers are difficult to interpret and can lead to expensive and
potentially harmful investigations. Although doctors may be
reassured by negative testing when no disease is suspected,26
diagnostic tests yielding normal results make hardly any
difference to the level of reassurance of patients.25
What is the interpretation of an abnormal
result?
Interpreting an abnormal result is relatively straightforward if
there is a clear pretest hypothesis against which the test result
can be evaluated—for example, if assessing the likelihood of
serious infection in a child with a fever and abdominal pain.
This was best shown in a Dutch study of patients in whom the
raised ESR seemed to confirm an initial diagnosis as opposed
to showing unexpected disease.29 The difficulty lies in the
interpretation of an “incidental” abnormality, when no specific
disease is suspected, as in our hypothetical case. A systems
inquiry, focusing on infection, autoimmune conditions, and
malignancy, plus examination of the patient should generally
point towards specific investigations. If history and examination
yield no clues, it is reasonable to wait and see if symptoms
develop rather than conduct an extensive search for occult
disease. This investigation plan is supported by studies that have
followed up patients with unexplained increases in levels of
inflammatory markers. In one large (n=1462) study of
asymptomatic Swedish women, 60% of these increases were
transitory; none of the women with a raised ESR developed
cancer; and in 46% of the women the cause of the increase
remained undiagnosed over six years of observation.30
In cases with markedly raised levels of inflammatory markers
(such as ESR >100 mm/h) the likelihood of disease is much
higher. The diagnoses found in these conditions depend on study
setting, but include infection (33-60%), inflammatory disease
(14-30%), and malignancy (5-28%).7 24 31-33 No diagnosis is
found in fewer than 3% of patients with an ESR of >100 mm/h.
In most patients, the diagnosis is likely to be clinically apparent;
once again, history, examination, focused investigations, and
careful follow-up should be sufficient to establish a clear
diagnosis.
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Outcome
The patient was asked to reattend surgery. His headache had
settled, though he still felt non-specifically unwell. Nothing
untoward was found on history or examination. He gradually
improved over the next two weeks without treatment or further
investigation. Measurement of ESR was not repeated.
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Tables
Table 1| Reviews of inflammatory markers for diagnosis of specific conditions
OutcomeStudy typeSettingTarget condition (test)
Summary sensitivity 73%, specificity 76%Systematic review (6 reports; 466
patients)8
Secondary careChorioamnionitis in premature
delivery (CRP)
Likelihood ratio of raised CRP 3.2 (95% CI 2.7 to 3.7);
negative likelihood ratio 0.33 (0.23 to 0.49).10 Similar
results in second review9
Systematic reviews (5/6 reports on
CRP/ESR; 1379 patients having CRP)9
10
Secondary careSerious infections in febrile children
(CRP, ESR)
Pooled odds ratio for raised CRP and bacterial
infection 2.6 (1.2 to 5.6)
Systematic review (8 reports; 1230
patients)11
Secondary careBacterial chest infection in children
(CRP)
Likelihood ratio of raised CRP 2.1 (95% CI 1.8 to 2.4);
negative likelihood ratio 0.33 (0.25 to 0.43). Similar
results in an earlier review13 and a subsequent study
in primary care14
Systematic review (8 reports, with 2194
patients)12
Primary care; accident and
emergency departments
Bacterial chest infection in adults
(CRP)
Likelihood ratio of raised CRP increases as CRP
increases: 5.2 (1.7 to 16) for CRP >25 mg/L. For
normal CRP, 0.44 to 0.47. For ESR >20 mm/h, 3.8
(1.8 to 8.1)
Systematic review of all features of
appendicitis, including 5 studies of CRP,
1 of ESR; 730 and 162 children
repsectivley15
Secondary care (mainly
emergency departments)
Appendicitis in children with
abdominal pain (CRP, ESR)
Summary likelihood ratio of ESR >70 mm/h 11 (1.6 to
79).
Systematic review of all features of
osteomyelitis, including 3 studies of ESR;
92 patients16
Secondary care (inpatients
and outpatients)
Osteomyelitis of the leg in diabetes
(ESR)
ESR >30 mm/h: sensitivity 0.82 (0.65 to 0.93),
specificity 0.85 (0.78 to 0.91); CRP >100 mg/L 0.96
(0.78 to 1.0), 0.92 (0.85 to 0.96). No patient with an
infected arthroplasty had negative result on both tests
Cohort study of 178 patients; 202
arthroplasties 17
Secondary careInfection in revision hip
arthroplasties (CRP, ESR)
CRP=C reactive protein; ESR= erythrocyte sedimentation rate. 95% CI= 95% confidence interval.
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Table 2| Community and primary care studies investigating the diagnostic role of inflammatory markers as diagnostic or screening tools
for non-specific disease
OutcomeParticipantsStudy typeSetting (test)
44 had persistently raised ESR; of these, 10 subsequently
developed disease (4 myocardial infarctions, 3 ankylosing
spondylitis, and one each of inflammatory bowel disease,
psoriasis, benign monoclonal gammopathy)
1000 healthy men aged 18-33 years:
yearly ESR measurement
Prospective study, 15 year
follow-up27
Israeli airmen (ESR)
9 subjects had an ESR >30 mm/h for ≥6 months; a previously
undiagnosed illness was identified in 4 of these (2 polymyalgia,
1 pancytopaenia, 1 anaemia)
100 healthymen and women aged over
70 years
Prospective study, 12 month
follow-up28
Community study of ageing
in the US (ESR)
ESR values were on average higher in those with malignancy
or inflammatory diseases. Almost all diagnoses
“revealed” by the raised ESR had been suspected at the initial
consultation before the ESR result was known
362 patients presenting with a new
complaint for which the general
practitioner considered ESR to be
indicated
Prospective study, 3 month
follow-up29
Primary care in the
Netherlands (ESR)
ESR=erythrocyte sedimentation rate.
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